Neutra Corp’s Subsidiary Neutra Life Sciences Executes New Women’s Health Joint Venture and Expands Trial Portfolio

About this update from Neutra Corp.

HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced a series of operational milestones at its wholly owned subsidiary, Neutra Life Sciences, a clinical research Site Management Organization (SMO). Following its 2025 launch and early-stage growth, Neutra Life Sciences has proven its operational excellence with multiple clinical trial. Since its formation, Neutra Life Sciences has built the operational infrastructure required to support a sustainable, scalable site network, including standardized site operating procedures, an expanding investigator base, and a consistent track record of regulatory-compliant trial execution. This foundation has allowed the subsidiary to move from an early-growth phase into a stable operating model capable of supporting a broader, more diverse clinical trial portfolio. As part of this expansion, Neutra Life Sciences executed a new joint venture partnership with Women's Healthcare Center of Baytown, which expanded its site network dedicated into women's health. The new site broadens Neutra Life Sciences' specialty footprint beyond its existing network and reflects increasing demand from sponsors for clinical trial access in women's health research. "Growing into a multi-therapeutic site network was done with intention," said Sydney Jim, President and CEO of Neutra Life Sciences. "This new joint venture and the launch of our women's health site solidify our growth strategy, and we are proud to extend OB/GYN clinical trial access to patients." Alongside this expansion, Neutra Life Sciences was awarded new clinical trials in Oncology, Dermatology, Pulmonology, and Women's Health, broadening the range of conditions studied across its site network. The subsidiary also secured new contracts with new sponsors, further diversifying its sponsor relationships and strengthening its trial pipeline heading into the second half of 2026. "Being awarded studies in new therapeutic areas and signing new sponsor contracts is a direct result of the operational discipline we've built over the past year," added Sydney Jim. "Each new study and each new sponsor relationship adds depth to our pipeline and reinforces Neutra Life Sciences as a dependable SMO partner." Recent milestones at Neutra Life Sciences include:

View stock analysis, news, and events for Neutra Corp.